Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide

• Published in: British journal of clinical pharmacology Vol. 62; no. 5; pp. 567 - 572
• Main Authors: Zhang, Wei, He, Yi‐Jing, Han, Chun‐Ting, Liu, Zhao‐Qian, Li, Qing, Fan, Lan, Tan, Zhi‐Rong, Zhang, Wei‐Xia, Yu, Bang‐Ning, Wang, Dan, Hu, Dong‐Li, Zhou, Hong‐Hao
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.11.2006; Blackwell Science; Blackwell Science Inc
• Subjects: Adult; Biological and medical sciences; Cyclohexanes - administration & dosage; Cyclohexanes - pharmacokinetics; Cyclohexanes - therapeutic use; Diabetes Mellitus - drug therapy; Diabetes Mellitus - genetics; Humans; Hypoglycemic Agents - therapeutic use; Male; Medical sciences; nateglinide; Organic Anion Transporters - genetics; Pharmacogenetics; pharmacokinetics; Pharmacology. Drug treatments; Phenylalanine - administration & dosage; Phenylalanine - analogs & derivatives; Phenylalanine - pharmacokinetics; Phenylalanine - therapeutic use; Polymorphism, Single Nucleotide - genetics; SLCO1B1 polymorphism; Solute Carrier Organic Anion Transporter Family Member 1b1; Hypoglycemic agent; Genetic variability; Genotype; SLCO1B1 polymorphism; Pharmacokinetics; Nateglinide; Polymorphism
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/j.1365-2125.2006.02686.x

Aims Nateglinide is a meglitinide analogue with antidiabetic action. A recent study showed that SLCO1B1 (which codes the OATP1B1 gene, also known as OATP‐C, OATP2) is a major determinant which markedly affects the pharmacokinetics of repaglinide. Our objective was to assess the association between single nucleotide polymorphisms (SNPs) of SLCO1B1 and the pharmacokinetics of nateglinide. Methods Seventeen healthy volunteers with different SLCO1B1 genotypes (11 with 521TT, four with 521TC and two with 521CC) were enrolled in this study. Each was given a single oral dose of 90 mg nateglinide. Plasma concentrations of nateglinide were measured up to 8 h by HPLC. Results The Cmax and AUC(0,∞) of nateglinide were 83% (P = 0.002) and 82% (P = 0.001) higher in the SLCO1B1521TC subjects (n = 4), and 76% (P = 0.016) and 108% (P = 0.001) higher in the SLCO1B1521CC subjects (n = 2) than in the SLCO1B1521TT subjects (n = 11), respectively. The t1/2 of nateglinide in SLCO1B1521CC subjects was 78% longer than that in 521TT subjects (P = 0.036). The difference in tmax values among the three genotypic groups was not statistically significant. Conclusions Our results suggest that OATP1B1‐mediated hepatic uptake of nateglinide may be the prior step for its metabolism and elimination. SLCO1B1521T > C SNP might play an important role in the pharmacokinetics of nateglinide.